NAMS
NewAmsterdam Pharma Company N.V. trades as NAMS and has a market capitalization of $3.44 B, making it the #1705 largest US-listed company by market value. In its fiscal 2025 annual report the company posted revenue of $22.50M, down 50.6% from the prior year and net income of -$203.00M. This page tracks NewAmsterdam Pharma Company N.V. through 386 SEC filings, with financial statements and metrics updated as new reports are filed.
Net profit margin compressed from -22.0% to -902.1% over the same period - every figure below comes from the company's audited annual filings.
| Filing | Type | Filed |
|---|---|---|
| Insider sale notice | 144 | 2026-05-26 |
| SCHEDULE 13D/A | - | 2026-05-14 |
| Major company event | 8-K | 2026-05-07 |
| Quarterly report | 10-Q | 2026-05-07 |
| Annual report to shareholders | ARS | 2026-05-06 |
| Proxy statement | DEF 14A | 2026-05-06 |
| SCHEDULE 13G/A | - | 2026-05-06 |
| Major company event | 8-K | 2026-04-24 |
NewAmsterdam Pharma to Participate at Upcoming Investor Conferences in May
The Compensation Committee of NewAmsterdam’s Board of Directors also approved the grant of restricted stock units covering an aggregate of 15,400 of NewAmsterdam’s ordinary shares to five non-executive new hires. The restricted stock units were granted as an inducement material to the employees’ acceptance of employment with NewAmsterdam pursuant to the 2024 Inducement Plan and in accordance with Nasdaq Listing Rule 5635(c)(4).
NewAmsterdam Pharma to Present at the 25th Annual Needham Virtual Healthcare Conference
The Compensation Committee of NewAmsterdam’s Board of Directors also approved the grant of restricted stock units covering an aggregate of 3,200 of NewAmsterdam’s ordinary shares to two non-executive new hires. The restricted stock units were granted as an inducement material to the employees’ acceptance of employment with NewAmsterdam pursuant to the 2024 Inducement Plan and in accordance with Nasdaq Listing Rule 5635(c)(4).
The largest companies sharing NewAmsterdam Pharma Company N.V.'s SEC industry classification (pharmaceutical preparations).
NewAmsterdam Pharma Company N.V. (NAMS) has a market capitalization of $3.44 B as of 2026-06-10, ranking #1705 among US-listed companies.
NewAmsterdam Pharma Company N.V. reported revenue of $22.50M for fiscal year 2025, a decrease of 50.6% year over year.
In its latest fiscal year NewAmsterdam Pharma Company N.V. reported a net loss of $203.00M.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
Dig into the full income statement, balance sheet, and cash flow statement with annual and quarterly views.
– Decisions on regulatory approval from EMA, UK, and Switzerland for obicetrapib and obicetrapib/ezetimibe fixed - dose combination expected in 2H26, and based on the outcomes, with potential launches by Menarini in 4Q26 in Germany and the UK –